- ACTengine® IMA203 TCR-T monotherapy
against PRAME showed 50% confirmed objective response rate (cORR)
at or above target dose in different solid cancers in an interim
clinical update in Phase 1a and Phase 1b in October 2022
- ACTengine® IMA203 TCR-T clinical
data update on all three ongoing IMA203 Phase 1b cohorts (Cohort A:
1st-gen monotherapy, Cohort B: combination with a checkpoint
inhibitor, Cohort C: 2nd-gen monotherapy), and identification of
most promising cohort to advance towards pivotal trials is planned
for 2H 2023; prioritization of patient treatment with 1st and
2nd-generation monotherapy
- Expansion of cell therapy
manufacturing capabilities with construction of an in-house GMP
manufacturing facility for registration-directed and commercial
production of ACTengine® TCR-T products expected to be operational
in 2024
- Phase 1 clinical trial for first
TCR Bispecific candidate, TCER® IMA401 targeting MAGEA4/8 developed
in collaboration with Bristol Myers Squibb commenced in May 2022;
TCER® IMA402 targeting PRAME on track for CTA1 submission in 2Q
2023
- Strategic collaboration with
Bristol Myers Squibb has been expanded in June 2022 to develop
allogeneic and autologous cell therapy programs; Immatics received
$80 million upfront payment and is eligible for milestone payments
as well as tiered royalties
- $110 million underwritten offering
successfully completed in October 2022
- Cash and cash equivalents as well
as other financial assets amount to $386.3 million2 (€362.2
million) as of December 31, 2022, and projects cash runway into
2025
Tuebingen,
Germany and Houston, TX,
March
21,
2023 – Immatics
N.V. (NASDAQ: IMTX; “Immatics”), a clinical-stage biopharmaceutical
company active in the discovery and development of T
cell-redirecting cancer immunotherapies, today provided a business
update and reported financial results for the quarter and full year
ended December 31, 2022.
Harpreet Singh, Ph.D., CEO and Co-Founder of
Immatics commented, “Our ACTengine® IMA203 clinical trial has
gained significant traction over the past year with promising data
for our monotherapy candidate targeting PRAME. As we continue
demonstrating the potential of our first- and second-generation
product candidates in patients, we have commenced establishing our
in-house GMP cell therapy manufacturing facility in Houston, TX.
This positions us to scale our cell therapies for
registration-directed trials and commercial supply. In addition, we
have significantly advanced our clinical TCR Bispecifics pipeline
with one TCER® program targeting MAGEA4/8 now in the clinic and a
second TCER® program targeting PRAME commencing clinical studies
this year. We demonstrated our ability to execute and deliver on
our goals in 2022 and look forward to continuing on this path in
2023.”
Full Year
2022 and Subsequent
Company Progress
Adoptive Cell Therapy
Programs
- ACTengine®
IMA203 (PRAME) –
Immatics is investigating IMA203 TCR-T in a Phase 1b trial
including three ongoing dose expansion cohorts. Immatics’ focus for
2023 is to advance its monotherapy product candidates,
1st-generation IMA203 TCR-T (Cohort A) and 2nd-generation IMA203CD8
TCR-T (Cohort C) in the last-line therapy setting. Data generated
throughout 2023 with longer follow-up to assess durability of
response is intended to identify the most promising cohort to
advance towards pivotal trials and potential commercialization. The
clinical data update on all three cohorts is planned for 2H
2023.
IMA203 TCR-T
monotherapy (Cohort
A):
- In October 2022, Immatics provided
an interim update on the ongoing IMA203 TCR-T monotherapy trial
covering data from 27 patients in the completed Phase 1a dose
escalation and the first 5 patients in the Phase 1b dose expansion
trial.
- Treatment with IMA203 continued to
show a manageable tolerability profile in a heavily pre-treated
patient population.
- A confirmed objective response rate
(cORR) of 50% (6/12) was observed at target dose or above across
Phase 1a and Phase 1b.
- Confirmed responses were observed
in 4/5 (80%) patients in the Phase 1b trial alone with early signs
of prolonged durability at 12 weeks of follow-up with all responses
ongoing at data cut-off.
- Manufacturing enhancements
implemented in Phase 1b (including monocyte depletion) resulted in
higher infused T cell doses and significantly higher T cell peak
expansion and persistence.
- Confirmed responses were observed
across different solid tumor types: cutaneous melanoma, ovarian
cancer, head and neck cancer, uveal melanoma, and synovial
sarcoma.
IMA203 TCR-T
in combination
with nivolumab (Cohort
B):
- In May 2022, the first patient was
treated with IMA203 in combination with the PD-1 immune checkpoint
inhibitor nivolumab at the provisional recommended Phase 2 dose
(RP2D).
- Immatics is currently prioritizing
patient treatment with IMA203 and IMA203CD8 TCR-T monotherapy in a
last-line therapy setting but is considering further investigation
of a combination with nivolumab as a front-line therapy.
IMA203CD8
2nd-generation
TCR-T monotherapy (Cohort
C):
- IMA203CD8 is Immatics’
2nd-generation monotherapy product candidate directed against PRAME
in which IMA203 engineered T cells are co-transduced with a CD8αβ
co-receptor that engages functional CD4 and CD8 T cells.
- The first patient was treated in
August 2022. As IMA203CD8 is a novel product candidate under a new
IND amendment, a staggered enrollment was implemented; the
treatment of three patients at dose level 3 (DL3) has been
completed. Patients are currently being treated at DL4a (up to
0.8x109 TCR-T cells/m2 body surface area).
- Cell
Therapy
Manufacturing – Immatics is further enhancing its cell
therapy manufacturing process and capabilities.
- Immatics proprietary manufacturing
process is designed to produce T cells within one week, followed by
a recently implemented one-week quality control release testing
(previously two weeks). This allows Immatics to shorten the
turnaround time and to provide the cell therapy product candidate
to patients faster.
- Immatics is building a
state-of-the-art 100,000 square foot research and commercial GMP
manufacturing facility in the metropolitan area of Houston, Texas.
The facility is intended to manufacture Immatics’ ACTengine® IMA203
products as well as other future autologous and allogeneic cell
therapy product candidates for early-stage and
registration-directed clinical trials as well as for initial
commercial supply. The facility is designed for flexibility and can
be expanded in a modular fashion. The GMP manufacturing facility is
expected to be operational in 2024.
- ACTengine® IMA201
(MAGEA4/8) – The Phase 1a dose
escalation cohort at target dose is ongoing. Immatics plans to
discontinue this program after treatment of the remaining patients
already enrolled in the clinical trial in order to focus on its TCR
Bispecific program TCER® IMA401 addressing the identical target
peptide derived from MAGEA4/8 as IMA201.
- ACTengine® IMA204 (COL6A3
exon 6) – Immatics and the University of Pennsylvania
co-authored a research paper published in the peer-reviewed
journal, Science Translational Medicine highlighting the
identification of a novel proprietary HLA-A*02:01-presented target,
collagen type VI alpha-3 (COL6A3) using Immatics’ proprietary
discovery platforms, XPRESIDENT® and XCEPTOR®. COL6A3 is expressed
at high target density across multiple solid cancer indications and
specific to the tumor stroma. Targeting tumor stroma provides an
innovative therapeutic opportunity to disrupt the tumor
microenvironment. The COL6A3-directed TCR-T candidate ACTengine®
IMA204, developed by Immatics, was able to eliminate tumor cells at
physiological target levels in in vitro studies and in vivo mouse
models. The company has delayed the IND submission for IMA204 to
consolidate its clinical resources on accelerating the clinical
development of its PRAME-directed product candidates.
- ACTallo®
pipeline – In June 2022, Immatics
entered into two strategic collaborations with the goal of
developing transformative next-generation allogeneic gamma delta
TCR-T/CAR-T programs with enhanced persistence, safety and potency,
by combining Immatics’ proprietary ACTallo® platform with Bristol
Myers Squibb’s next-generation technologies and Editas Medicine’s
CRISPR gene editing technology.
- Immatics entered into a new
multi-program collaboration with Bristol Myers Squibb to develop
allogeneic TCR-T/CAR-T programs using Immatics’ proprietary
ACTallo® platform and Bristol Myers Squibb’s technologies. Immatics
received $60 million upfront payment and is eligible for up to $700
million per program in milestone payments as well as tiered
royalties. Immatics may also develop its own ACTallo®-based
programs outside of the collaboration.
- The strategic research
collaboration and licensing agreement with Editas Medicine, Inc.,
combines Immatics’ ACTallo® platform with Editas Medicine’s CRISPR
gene editing technology.
Autologous TCR-T
pipeline
- Immatics and Bristol Myers Squibb
expanded their autologous T cell receptor-based therapy (TCR-T)
collaboration signed in 2019 by including one additional TCR-T
target discovered by Immatics. Immatics received an upfront payment
of $20 million and is eligible for milestone payments as well as
royalties.
- In October 2022, GSK provided
Immatics with notice of its decision to terminate their
collaboration. Initially announced on February 20, 2020, the terms
of the agreement included a €45 million (~$50 million) upfront
payment to Immatics and the potential for additional milestone and
royalty payments in return for access to two of Immatics’ TCR-T
programs. As communicated to Immatics, GSK’s decision was made
unrelated to the programs and the progress achieved in the
collaboration to date. The termination was effective on December
26, 2022. GSK transferred the rights for both TCR-T programs back
to Immatics.
TCR Bispecifics
Programs
Immatics’ TCER® candidates are next-generation,
half-life extended TCR Bispecific molecules designed to maximize
efficacy while minimizing toxicities in patients through its
proprietary format using a low-affinity T cell recruiter and a
high-affinity TCR domain.
- TCER®
IMA401 (MAGEA4/8) – Immatics
initiated a Phase 1 trial in May, to evaluate safety, tolerability
and initial anti-tumor activity of its T cell engaging receptor
(TCER®) IMA401 for patients with recurrent and/or refractory solid
tumors. IMA401 is being developed in collaboration with Bristol
Myers Squibb.
- TCER® IMA402
(PRAME) – A comprehensive preclinical data set was
presented at the European Society for Medical Oncology (ESMO)
congress in September 2022. The TCER® candidate IMA402 showed
potent and selective activity against PRAME-positive tumor cell
lines in vitro, high anti-tumor activity in in vivo mouse models,
low target-independent T cell engager-associated cytokine release
and favorable pharmacodynamic characteristics. The submission of
the CTA1 application for the Phase 1/2 trial is on track for 2Q
2023. Immatics plans to start the trial in 2H 2023 with a flexible
dose escalation scheme for accelerated clinical development.
- TCER® IMA403 and TCER®
IMA40x – Immatics continues to develop several
innovative preclinical TCER® product candidates against so far
undisclosed targets for their proprietary and/or partnered
pipeline. IMA403 is in advanced preclinical development with
proof-of-concept studies ongoing. Additionally, TCER® engineering
and preclinical testing is ongoing for further TCER® candidates,
IMA40x, targeting peptides presented by HLA-A*02:01 and other
HLA-types.
Corporate Development
- Immatics successfully completed an
underwritten public offering in October 2022, raising approximately
$110 million before deducting underwriting discount and offering
expenses. The offering included participation from investors
including Armistice Capital Master Fund Ltd., Dellora Investments,
EcoR1 Capital, Nantahala Capital, Perceptive Advisors, Rock Springs
Capital, RTW Investments, LP, Samsara BioCapital, SilverArc
Capital, Sofinnova Investments, Wellington Management, 683 Capital
and other specialist biotech investors.
- Pursuant to Dievini Hopp Biotech
Holding’s rights under the business combination in 2020, dievini
has designated Mathias Hothum, Ph.D., for election as a director at
the 2023 annual general meeting of the shareholders in June 2023,
as successor to Friedrich von Bohlen und Halbach, Ph.D. Dr. Hothum
has been the Managing Director of dievini Hopp Biotech Holding,
which manages the life science activities and investments of
Dietmar Hopp and his family. He is also the Managing Director of
several investment and consulting companies. Dr. Hothum holds a
Ph.D. in Pharmaceutical Economics and Medical Sociology from the
University of Magdeburg, Germany.
Full Year 2022 Financial
Results
Cash Position: Cash and cash equivalents as well
as other financial assets total €362.2 million ($386.3 million2) as
of December 31, 2022 compared to €145.1 million ($154.8 million2)
as of December 31, 2021. The increase is mainly due to our public
offering and upfront payments for collaborations, partly offset by
our ongoing research and development activities. The Company
projects a cash runway into 2025.
Revenue: Total revenue, consisting of revenue
from collaboration agreements, was €172.8 million ($184.3 million2)
for the year ended December 31, 2022, compared to €34.8 million
($37.1 million2) for the year ended December 31, 2021.
Research and Development Expenses: R&D
expenses were €106.8 million ($113.9 million2) for the year ended
December 31, 2022, compared to €87.6 million ($93.4 million2) for
the year ended December 31, 2021. The increase mainly resulted from
higher costs associated with the advancement of the clinical and
pre-IND pipeline of ACTengine® and TCER® candidates.General and
Administrative Expenses: G&A expenses were €36.1 million ($38.5
million2) for the year ended December 31, 2022, compared to €33.8
million ($36.1 million2) for the year ended December 31, 2021.
Net Profit and Loss: Net profit was €37.5
million ($40.0 million2) for the year ended December 31, 2022,
compared to a net loss of €93.3 million ($99.5 million2) for the
year ended December 31, 2021. The improvement resulted mainly from
the one-time license fee income in connection with the IMA401
collaboration with Bristol Myers Squibb, as well as the recognition
of remaining deferred revenue in connection with the termination of
the GSK collaboration.
Full financial statements can be found in the
Annual Report on Form 20-F filed with the Securities and Exchange
Commission (SEC) and published on the SEC website under
www.sec.gov.
2 All amounts translated using the exchange rate
published by the European Central Bank in effect as of December 31,
2022 (1 EUR = 1,0666 USD).
Upcoming Investor ConferencesKempen Life
Sciences Conference, Amsterdam – April 25-26, 2023Bank of America
Health Care Conference, Las Vegas (NV) – May 9-11, 2023Jefferies
Global Healthcare Conference, New York (NY) – June 7-9, 2023
To see the full list of events and
presentations, visit
www.investors.immatics.com/events-presentations.
About ImmaticsImmatics combines
the discovery of true targets for cancer immunotherapies with the
development of the right T cell receptors with the goal of enabling
a robust and specific T cell response against these targets. This
deep know-how is the foundation for our pipeline of Adoptive Cell
Therapies and TCR Bispecifics as well as our partnerships with
global leaders in the pharmaceutical industry. We are committed to
delivering the power of T cells and to unlocking new avenues for
patients in their fight against cancer.
Immatics intends to use its website
www.immatics.com as a means of disclosing material non-public
information. For regular updates you can also follow us on Twitter,
Instagram and LinkedIn.
Forward-Looking
StatementsCertain statements in this press release may be
considered forward-looking statements. Forward-looking statements
generally relate to future events or Immatics’ future financial or
operating performance. For example, statements concerning the
timing of product candidates and Immatics’ focus on partnerships to
advance its strategy are forward-looking statements. In some cases,
you can identify forward-looking statements by terminology such as
“may”, “should”, “expect”, “intend”, “will”, “estimate”,
“anticipate”, “believe”, “predict”, “potential” or “continue”, or
the negatives of these terms or variations of them or similar
terminology. Such forward-looking statements are subject to risks,
uncertainties, and other factors which could cause actual results
to differ materially from those expressed or implied by such
forward looking statements. These forward-looking statements are
based upon estimates and assumptions that, while considered
reasonable by Immatics and its management, are inherently
uncertain. New risks and uncertainties may emerge from time to
time, and it is not possible to predict all risks and
uncertainties. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to, various factors beyond management's control including general
economic conditions and other risks, uncertainties and factors set
forth in filings with the SEC. Nothing in this presentation should
be regarded as a representation by any person that the
forward-looking statements set forth herein will be achieved or
that any of the contemplated results of such forward-looking
statements will be achieved. You should not place undue reliance on
forward-looking statements, which speak only as of the date they
are made. Immatics undertakes no duty to update these
forward-looking statements.
For more information, please
contact:
Media and Investor Relations Contact |
|
Jacob Verghese or Eva Mulder |
|
Trophic Communications |
|
Phone: +49 151 7441 6179 |
|
immatics@trophic.eu |
|
Immatics N.V. |
|
Anja Heuer |
Jordan Silverstein |
Senior Director Corporate Communications |
Head of Strategy |
Phone: +49 89 540415-606 |
Phone: +1 281 810 7545 |
media@immatics.com |
InvestorRelations@immatics.com |
Immatics N.V. and
subsidiariesCondensed Consolidated Statement of
Profit/(Loss) of Immatics N.V.
|
|
|
|
|
Year ended December 31, |
|
2022 |
2021 |
2020 |
|
(Euros in thousands, except share and
pershare data) |
Revenue from collaboration
agreements |
172,831 |
34,763 |
31,253 |
Research and development
expenses |
(106,779) |
(87,574) |
(67,085) |
General and administrative
expenses |
(36,124) |
(33,808) |
(34,186) |
Other income |
26 |
325 |
303 |
|
|
|
|
Operating
result |
29,954 |
(86,294) |
(69,715) |
Change in fair value of liabilities for
warrants |
10,945 |
(10,990) |
17,775 |
Share listing
expense |
— |
— |
(152,787) |
Other financial
income |
9,416 |
5,675 |
2,949 |
Other financial
expenses |
(8,279) |
(1,726) |
(10,063) |
|
|
|
|
Financial
result |
12,082 |
(7,041) |
(142,126) |
|
|
|
|
Profit/(loss) before
taxes |
42,036 |
(93,335) |
(211,841) |
Taxes on
income |
(4,552) |
— |
— |
|
|
|
|
Net
profit/(loss) |
37,514 |
(93,335) |
(211,841) |
Attributable
to: |
|
|
|
Equity holders of
the parent |
37,514 |
(93,335) |
(211,284 ) |
Non-controlling
interest |
|
— |
(557) |
Net profit/(loss) per
share: |
|
|
|
Basic |
0.56 |
(1.48) |
(4.40) |
Diluted |
0.55 |
(1.48) |
(4.40) |
Immatics N.V. and
subsidiariesCondensed Consolidated Statement of
Comprehensive
Income/(Loss)
of Immatics N.V.
|
|
|
|
|
Year ended December 31, |
|
2022 |
2021 |
2020 |
|
(Euros in thousands) |
Net
profit/(loss) |
37,514 |
(93,335) |
(211,841) |
Other comprehensive income/(loss) |
|
|
|
Items that may be reclassified subsequently to profit or loss |
|
|
|
Currency translation differences from foreign
operations |
2,464 |
3,514 |
(6,689 ) |
|
|
|
|
Total comprehensive income/(loss) for the
year |
39,978 |
(89,821) |
(218,530) |
Attributable to: |
|
|
|
Equity holders of the
parent |
39,978 |
(89,821) |
(217,973 ) |
Non-controlling
interest |
— |
— |
(557) |
Immatics N.V. and
subsidiariesCondensed Consolidated Statement of
Financial Position of Immatics N.V.
|
|
|
|
As of |
|
December 31, 2022 |
December 31, 2021 |
|
(Euros in thousands) |
Assets |
|
|
Current assets |
|
|
Cash and cash
equivalents |
148,519 |
132,994 |
Other financial
assets |
213,686 |
12,123 |
Accounts
receivables |
1,111 |
682 |
Other current
assets |
13,838 |
6,408 |
|
|
|
Total current
assets |
377,154 |
152,207 |
Non-current assets |
|
|
Property, plant and
equipment |
13,456 |
10,506 |
Intangible
assets |
1,632 |
1,315 |
Right-of-use assets
|
13,033 |
9,982 |
Other non-current
assets |
2,545 |
636 |
|
|
|
Total non-current
assets |
30,666 |
22,439 |
|
|
|
Total
assets |
407,820 |
174,646 |
|
|
|
Liabilities and shareholders’ equity |
|
|
Current liabilities |
|
|
Accounts
payables |
13,056 |
11,624 |
Deferred
revenue |
64,957 |
50,402 |
Liabilities for
warrants |
16,914 |
27,859 |
Lease
liabilities |
2,159 |
2,711 |
Other current
liabilities |
9,366 |
2,552 |
|
|
|
Total current
liabilities |
106,242 |
95,148 |
Non-current liabilities |
|
|
Deferred
revenue |
75,759 |
48,225 |
Lease
liabilities |
12,403 |
7,142 |
Other non-current
liabilities |
42 |
68 |
|
|
|
Total non-current
liabilities |
88,204 |
55,435 |
Shareholders’ equity |
|
|
Share capital |
767 |
629 |
Share premium |
714,177 |
565,192 |
Accumulated
deficit |
(500,299) |
(537,813) |
Other reserves |
(1,481) |
(3,945) |
|
|
|
Total shareholders’
equity |
213,164 |
24,063 |
|
|
|
Total liabilities and shareholders’
equity |
407,820 |
174,646 |
|
|
|
Immatics N.V. and
subsidiariesCondensed Consolidated Statement of
Cash Flows of Immatics N.V.
|
|
|
|
|
Year ended December 31, |
|
|
2022 |
2021 |
2020 |
|
|
(Euros in thousands) |
|
Cash flows from operating activities |
|
|
|
|
Net
profit/(loss) |
37,514 |
(93,335) |
(211,841) |
|
Taxes on income |
4,522 |
— |
— |
|
Profit/(loss) before
tax |
42,340 |
(93,335) |
(211,841) |
|
Adjustments for: |
|
|
|
|
Interest
income |
(2,476) |
(133) |
(850) |
|
Depreciation and
amortization |
6,967 |
5,260 |
4,424 |
|
Interest
expenses |
1,038 |
566 |
289 |
|
Share listing
expense |
— |
— |
152,787 |
|
Equity settled share-based
payment |
22,570 |
26,403 |
22,908 |
|
MD Anderson compensation
expense |
— |
— |
45 |
|
(Decrease) Increase in other liabilities resulting from share
appreciation
rights |
— |
— |
(2,036) |
|
Payment related to share-based compensation awards previously
classified as
equity-settled |
— |
— |
(4,322) |
|
Net foreign exchange differences and expected credit
losses |
2,953 |
(2,408) |
437 |
|
Change in fair value of liabilities for
warrants |
(10,945) |
10,990 |
(17,775) |
|
Changes in: |
|
|
|
|
(Increase)/decrease in accounts
receivables |
(429) |
569 |
(294) |
|
(Increase) in other
assets |
(7,872) |
(483) |
(1,600) |
|
Increase/(decrease) in deferred revenue, accounts payables and
other
liabilities |
45,559 |
(31,784) |
(23,387) |
|
Interest
received |
1,649 |
175 |
808 |
|
Interest paid |
(695) |
(566) |
(289) |
|
Income tax paid |
(224) |
— |
— |
|
|
|
|
|
|
Net cash provided
by/(used in) operating
activities |
100,131 |
(84,746) |
(80,696) |
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
Payments for property, plant and
equipment |
(5,738) |
(5,106) |
(7,420) |
|
Payments for investments classified in Other financial assets
|
(216,323) |
(11,298) |
(58,087) |
|
Proceeds from maturity of investments classified in Other financial
assets |
12,695 |
24,448 |
49,662 |
|
Payments for intangible
assets |
(477) |
(551) |
(104) |
|
Proceeds from disposal of property, plant and
equipment |
52 |
— |
— |
|
|
|
|
|
|
Net cash (used in)/provided by investing
activities |
(209,791) |
7,493 |
(15,949) |
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
Proceeds from issuance of shares to equity
holders |
134,484 |
94 |
217,918 |
|
Transaction costs deducted from
equity |
(7,931) |
— |
(7,939) |
|
Repayment of lease
liabilities |
(2,843) |
(2,707) |
(2,096) |
|
|
|
|
|
|
Net cash provided
by/(used in) financing
activities |
123,710 |
(2,613) |
207,883 |
|
|
|
|
|
|
Net increase/(decrease) in cash and cash
equivalents |
14,050 |
(79,866) |
111,238 |
|
|
|
|
|
|
Cash and cash equivalents at beginning of the
year |
132,994 |
207,530 |
103,353 |
|
|
|
|
|
|
Effects of exchange rate changes on cash and cash equivalents and
expected credit
losses |
1,475 |
5,330 |
(7,061) |
|
|
|
|
|
|
Cash and cash equivalents at end of the
year |
148,519 |
132,994 |
207,530 |
|
|
|
|
|
|
Immatics N.V. and
subsidiariesCondensed Consolidated Statement of
Changes in Shareholders’ equity (deficit) of Immatics
N.V.
|
|
|
|
|
|
|
|
(Euros
in thousands) |
Sharecapital |
Sharepremium |
Accumulateddeficit |
Otherreserves |
Total
equity(deficit)attributabletoshareholdersof
the parent |
Non-controllinginterest
|
Totalshare-holders’equity(deficit)
|
Balance as of January 1,
2020 |
1,164 |
190,945 |
(233,194) |
(770) |
(41,855) |
1,020 |
(40,835) |
Other comprehensive
loss |
— |
— |
— |
(6,689) |
(6,689) |
— |
(6,689) |
Net loss |
— |
— |
(211,284) |
— |
(211,284) |
(557) |
(211,841) |
Comprehensive loss for the
year |
— |
— |
(211,284) |
(6,689) |
(217,973) |
(557) |
(218,530) |
Reorganization |
(833) |
833 |
— |
— |
— |
— |
— |
Issue of share
capital |
|
|
|
|
|
|
|
MD Anderson Share
Exchange |
7 |
501 |
— |
— |
508 |
(508) |
— |
PIPE Financing, net of transaction
costs |
104 |
89,973 |
— |
— |
90,077 |
— |
90,077 |
ARYA Merger, net of transaction
costs |
180 |
237,864 |
— |
— |
238,044 |
— |
238,044 |
SAR conversion |
7 |
(7) |
— |
— |
— |
— |
— |
|
|
|
|
|
|
|
|
Total issuance of share
capital |
298 |
328,331 |
— |
— |
328,629 |
(508) |
328,121 |
Equity-settled share-based
compensation |
— |
22,908 |
— |
— |
22,908 |
— |
22,908 |
Payments related to share-based compensation awards previously
classified as
equity-settled |
— |
(4,322) |
— |
— |
(4,322) |
— |
(4,322) |
MD Anderson milestone compensation
expense |
— |
— |
— |
— |
— |
45 |
45 |
|
|
|
|
|
|
|
|
Balance as of December 31,
2020 |
629 |
538,695 |
(444,478) |
(7,459) |
87,387 |
— |
87,387 |
|
|
|
|
|
|
|
|
Balance as of January 1,
2021 |
629 |
538,695 |
(444,478) |
(7,459) |
87,387 |
— |
87,387 |
Other comprehensive
income |
— |
— |
— |
3,514 |
3,514 |
— |
3,514 |
Net loss |
— |
— |
(93,335) |
— |
(93,335) |
— |
(93,335) |
Comprehensive loss for the
year |
— |
— |
(93,335) |
3,514 |
(89,821) |
— |
(89,821) |
Equity-settled share-based
compensation |
— |
26,403 |
— |
— |
26,403 |
— |
26,403 |
Share options
exercised |
— |
94 |
— |
— |
94 |
— |
94 |
|
|
|
|
|
|
|
|
Balance as of December 31,
2021 |
629 |
565,192 |
(537,813) |
(3,945) |
24,063 |
— |
24,063 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance as of January 1,
2022 |
629 |
565,192 |
(537,813) |
(3,945) |
24,063 |
— |
24,063 |
Other comprehensive
income |
— |
— |
— |
2,464 |
2,464 |
— |
2,464 |
Net profit |
— |
— |
37,514 |
— |
37,514 |
— |
37,514 |
Comprehensive income for the
year |
— |
— |
37,514 |
2,464 |
39,978 |
— |
39,978 |
Equity-settled share-based
compensation |
— |
22,570 |
— |
— |
22,570 |
— |
22,570 |
Share options exercised |
— |
311 |
— |
— |
311 |
— |
311 |
Issue of share capital – net of transaction
costs |
138 |
126,104 |
— |
— |
126,242 |
— |
126,242 |
|
|
|
|
|
|
|
|
Balance as of December 31,
2022 |
767 |
714,177 |
(500,299) |
(1,481) |
213,164 |
— |
213,164 |
1 Clinical Trial Application (CTA) is the European equivalent of
an Investigational New Drug (IND) application2 All amounts
translated using the exchange rate published by the European
Central Bank in effect as of December 31, 2022 (1 EUR = 1,0666
USD).
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From May 2023 to May 2023
Immatics NV (NASDAQ:IMTX)
Historical Stock Chart
From May 2022 to May 2023